|The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Plasma hepatocyte growth factor (HGF) levels during treatment are prognostic for overall survival among patients with renal cell carcinoma (RCC) being treated with interferon alpha with or without bevacizumab, according to research being presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.1
Elevated HGF levels, which are linked to a high rate of angiogenesis, are linked to worse survival rated among patients with RCC treated with interferon alpha and bevacizumab. For this analysis of the phase 3 ALLIANCE study (ClinicalTrials.gov Identifier: NCT00072046), researchers determined the link between changes of HGF levels during treatment and survival.
Of 310 patients, 148 of whom were treated with interferon alpha only and 162 of whom were treated with interferon alpha plus bevacizumab, the baseline HGF level was 161.4 pg/mL. HGF levels greater than the median at 4 weeks of treatment were associated with worse overall survival (14 months vs 27 months for median or lower levels).
While only 9 patients with baseline median or lower HGF levels had elevated levels by 4 weeks, 66 patients with baseline elevated HGF levels had median or lower levels at 4 weeks.
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks (19 months vs 13 months).
RELATED: In Focus: Cabozantinib for Renal Cell Carcinoma
The authors concluded that “HGF predicts for therapeutic benefit and represents a potential mechanism of resistance.”
Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.
- George DJ, Halabi S, Starr MD, et al. Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). J Clin Oncol. 2017;35(suppl; abstr 4522).